Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study

被引：0

作者：

Catamero, Donna ^{[1
]}

Benito, Patricia Blazquez ^{[2
]}

Shenoy, Samantha ^{[3
]}

Chastain, Katherine ^{[4
]}

Kruyswijk, Sandy ^{[5
]}

机构：

[1] Mt Sinai Hlth Syst, New York, NY USA

[2] Univ Hosp Salamanca, Salamanca, Spain

[3] Univ Calif San Francisco, San Francisco, CA USA

[4] Janssen Res & Dev, Raritan, NJ USA

[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NSP-05

引用

页码：S315 / S316

页数：2

共 50 条

[31] Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy
Hamadeh, S.
Shekarkhand, Tala
Rueda, Colin
Firestone, Ross
Wang, Alice
Korde, Neha
Hultcrantz, Malin
Lesokhin, Alexander
Mailankody, Sham
Hassoun, Hani
Shah, Urvi A.
Maclachlan, Kylee H.
Patel, Dhwani
Shah, Gunjan L.
Scordo, Michael
Lahoud, Oscar Boutros
Chung, David
Landau, Heather
Giralt, Sergio A.
Usmani, Saad Z.
Tan, Carlyn Rose
BLOOD, 2023, 142
[32] Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience
Lachenal, Florence
Lebreton, Pierre
Bouillie, Sylvie
Matteo, Gian
Aftisse, Hassina
Pascal, Laurent
Montes, Lydia
Macro, Margaret
Vignon, Marguerite
Harel, Stephanie
Fernandez, Mariana
Louni, Chanaz
Huart, Antoine
Perrot, Aurore
BLOOD, 2023, 142
[33] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau, Philippe
Usmani, Saad Z.
Garfall, Alfred L.
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas
Rosino, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martínez-López, Joaquín
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca I.
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa M.
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita Y.
BLOOD, 2021, 138
[34] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Usmani, Saad Z.
Garfall, Alfred
van de Donk, Niels
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar
Moreau, Philippe
Besemer, Britta
Martinez-Lopez, Joaquin
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
[35] Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
van de Donk, Niels W. C. J.
Chari, Ajai
Karlin, Lionel
Krishnan, Amrita Y.
Uttervall, Katarina
Chalopin, Thomas
Dachs, Laura Rosinol
Oriol, Albert
Matous, Jeffrey, V
Bhutani, Manisha
Rodriguez, Cesar
Carde, Natalia Quijano
Guo, Yue
Hodin, Caroline
Uhlar, Clarissa
Stephenson, Tara
Zuppa, Athena
Doyle, Margaret
Chastain, Katherine
Garfall, Alfred
BLOOD, 2024, 144 : 4735 - 4735
[36] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Cohen, Yael C.
Magen, Hila
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Ocio, Enrique M.
Yoon, Sung-Soo
Chu, Michael P.
Rodriguez-Otero, Paula
Avivi, Irit
Quijano Carde, Natalia A.
Kumar, Ashwini
Krevvata, Maria
Peterson, Michelle R.
Di Scala, Lilla
Scott, Emma
Hilder, Brandi
Vanak, Jill
Banerjee, Arnob
Oriol, Albert
Morillo, Daniel
Mateos, Maria-Victoria
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149
[37] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
Lebreton, P.
Lachenal, F.
Bouillie, S.
Pica, G. M.
Aftisse, H.
Pascal, L.
Montes, L.
Macro, M.
Johnson, N.
Harel, S.
Fernandez, M.
De Renzis, B.
Lioure, B.
Lazareth, A.
Javelot, M.
Louni, C.
Huart, A.
Perrot, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
[38] Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Usmani, Saad Z.
Garfall, Alfred L.
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Karlin, Lionel
Benboubker, Lotfi
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Elsayed, Yusri
Infante, Jeffrey
Goldberg, Jenna D.
Banerjee, Arnob
Mateos, Maria-Victoria
Krishnan, Amrita
LANCET, 2021, 398 (10301): : 665 - 674
[39] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[40] Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma
Tabbara, Nadeem
Singel, Michael
Allen, Natalie
Mooney, Kathy
Shedeck, Audra
Zukas, Amber
Campion, Kate
Sollenberger, Callan
Gocke, Christian Burris
Ali, Syed Abbas
Huff, Carol Ann
Imus, Philip H.
Waheed, Sarah
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →